Guangxi Yingkang takes the initiative to hand in the GMP certificate

Recently, CCTV reported that Guangdong Baoshantang Pharmaceutical Co., Ltd. (abbreviated as “Baoshantang”) was suspected of illegally extracting vitamin C Yinqiao tablet dry extract. On April 9, Guangyao Pharmaceutical Group’s subsidiaries Guangxi Yingkang Pharmaceuticals and Guangzhou Pharmaceutical Co., Ltd. At the same time, the industry issued a notice that its Victoria C Yinqiao tablets were all qualified according to the national pharmacopoeia standards. In addition, the five heavy metal projects such as lead, cadmium, arsenic, mercury, and copper that were added to the inspection also all met the national standards.

Guangxi Yingkang stated that GMP (Pharmaceutical Production Quality Management Specification) certification is a dynamic process management of pharmaceutical production. Although there was no problem with the quality of the drug, there was an unsatisfactory management of the upstream company. Therefore, on the morning of April 9, the company took the initiative to submit a GMP certificate to the regulatory authorities, requested rectification, and apologized to consumers at the same time. “Because Baoshan Tang forged production records and related documents, the means were extremely hidden. The company failed to discover the above-mentioned behavior of Baoshan Church in time, bringing a certain potential safety hazard to consumers.” It is reported that this is China's first initiative to hand in GMP. Certificate of drug company.

On March 26, CCTV reported on Baoshan Church’s alleged violative production of vitamin C Yinqiao tablet dry extract. Since Guangxi Yingkang is the downstream manufacturer of Baoshan Tongwei C Yinqiao Tablets Dry Extract, Yingkang and its parent company, Guanghua, have therefore become the target of public criticism. It is reported that after CCTV reported, Guangxi Yingkang has stopped selling for the first time, and all C-inch Yinqiao tablets and dry extracts were sealed for inspection and voluntary recall, according to Guangxi Yingkang’s announcement yesterday, as of April 8th. , Recalls and archives 13,232 pieces of Victoria C Yinqiao Tablets, with a recall rate of approximately 98%. Guangxi Yingkang stated that it will continue to ensure product 100% recall through various means.

The relevant person in charge of Guangxi Yingkang said in an interview with reporters: “After CCTV reported, the company immediately set up a task force and terminated the cooperation with Baoshan Church for the first time, immediately stopping the production and sales of Victoria C Yinqiao tablets. The dried paste and the finished product in the factory are immediately sealed; and immediately the third-party inspection of the V-Cycraker sheet is conducted.” In order to test whether the C-Cydrium silver sheet contains a lot of heavy metals such as lead, mercury, etc. The tablets were sent to the Guangxi Analytical, Testing and Research Center for testing. According to the standards specified in the “Chinese Pharmacopoeia (2010 Edition)”, “Heavy Metals and Harmful Elements” of medicinal herbs such as hawthorn and licorice, the test results all met the standards.

In fact, the GMP certificate is equivalent to the pharmaceutical company's qualifications and licenses for the production of drugs. Losing the certificate means that it can not be produced for a certain period of time. Due to the strict GMP certification requirements, many pharmaceutical companies have invested huge human and material resources in order to pass certification. . Persons in the pharmaceutical industry pointed out that due to the large number of testing indicators, it takes a certain amount of time for the drugs to produce test results. Cases of voluntary recalls are rare in China's pharmaceutical industry. There have been sporadic voluntary recalls, but the majority of companies are foreign pharmaceutical companies.